Sustained-release tramadol formulations with 24-hour efficacy

a tramadol and formulation technology, applied in the direction of dragees, coatings, pharmaceutical delivery mechanisms, etc., can solve the problems of low abuse potential of tramadol, inconsistent plasma drug concentration, and dependence of tramadol hcl

US20090047345A9Inactive Publication Date: 2009-02-19LABOPHARM BARBADOS LTD 36646
98 Cites 20 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
Publication Date
2009-02-19
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF THE INVENTION

[0001] This invention relates to a novel once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof. BACKGROUND OF THE INVENTION Tramadol Pharmaceutical Formulations

[0002] Tramadol hydrochloride (HCl) was developed by GrOnenthal GmbH, Germany. It has been marketed in Germany since 1977 (eg. Tramal™), and in the United States as Ultram® since 1995. The efficacy and safety profile of tramadol HCl make it highly suitable as a long-term treatment for chronic pain.

[0003] Tramadol HCl is a synthetic, centrally acting analgesic that has been shown to be effective in a variety of acute and chronic pain states. In particular, tramadol HCl, in both immediate and slow-release formulations, in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) (Roth SH “Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis”. J. Rheumatol 1998; 25:1358-1363. Wilder-Smith CH et al. “Treatmen...

Examples

example 1

A. Cross-Linking

[0090] High amylose starch (30.0 kg) containing about 70% wow of amylose (Cl AmyloGel 03003) is placed in a reactor. To this reactor is added water (55.0 1) containing sodium hydroxide (30.0 g) and sodium sulfate (2.40 kg). The resulting slurry is heated to a temperature of 30° C. Phosphorus oxychloride (22.5 g) is added to the reaction mixture which is reacted for one hour.

B. Chemical Modification, Hydroxyproylation

[0091] The crude reaction mixture from Part A is transferred into a hydroxypropylation reactor. The reaction mixture is heated to 40° C. over 30 minutes and the reaction is purged with nitrogen. After a full purge, propylene oxide (1.80 kg) is added. The reaction mixture is kept at 40° C. for 20 hours. The reaction mixture is neutralized with 0.1 N H2SO4 (1:2 v / v) to a pH of 5.5. The starch slurry is washed with a basket-centrifuge at a speed of 1200 rpm. The obtained starch cake is re-slurrified in 35 l of water and centrifuged a second time. The re...

example 2

A. Cross-Linking

[0094] High amylose starch (30.0 kg) containing about 70% w / w of amylose (Cl AmyloGel 03003) is placed in a reactor. To this reactor is added water (55.01) containing sodium hydroxide (30.0 g) and sodium sulfate (2.40 kg). The resulting slurry is heated to a temperature of 30° C. Sodium trimetaphosphate (45 g) is added to the reaction mixture which is reacted for one hour.

B. Chemical Modification, Hydroxyproylation

[0095] The crude reaction mixture from Part A is transferred into a hydroxypropylation reactor. The reaction mixture is heated to 40° C. over 30 minutes and the reaction is purged with nitrogen. After a full purge, propylene oxide (1.80 kg) is added. The reaction mixture is kept at 40° C. for 20 hours. The reaction mixture is neutralized with 0.1 N H2SO4 (1:2 v / v) to a pH of 5.5. The starch slurry is washed with a basket-centrifuge at a speed of 1200 rpm. The obtained starch cake is re-slurrified in 35 l of water and centrifuged a second time. The resu...

example 3

[0106] Formulations A, B, and C, as shown in Table 1, were manufactured according to the process set out above.

TABLE 1Recipes for Controlled Released Tramadol Formulations A, B and C.Formulation AFormulation BFormulation C%mg / tablet%mg / tablet%mg / tablet1) INGREDIENTCoreTramadol Hydrochloride5045509063.25151.8Contramid ®48.343.4748.386.9435.0584.1Hydrogenated Vegetable Oil0.750.6750.751.350.751.8Silica0.20.180.20.360.200.5Magnesium Stearate0.750.6750.751.350.751.8Core Total Weight100901001801002402) COATTramadol Hydrochloride21.155530.5611030.56148.5Silica0.200.520.200.720.201.0Kollidon SR ®51.42133.745.16162.5845.16219Xanthan Gum25.7266.8622.5881.322.58109.5Hydrogenated Vegetable Oil1.002.61.003.61.004.9Magnesium Stearate0.501.30.501.80.502.4Coat Total Weight100260100.003601004853) COATED TABLETTramadol Hydrochloride28.5710037.0420041.38300Contramid ®12.4243.4716.1086.9411.6084.1Hydrogenated Vegetable Oil0.943.2750.924.950.926.7Silica0.200.70.201.080.201.5Magnesium Stearate0.561.97...